JPWO2022101470A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022101470A5 JPWO2022101470A5 JP2023528666A JP2023528666A JPWO2022101470A5 JP WO2022101470 A5 JPWO2022101470 A5 JP WO2022101470A5 JP 2023528666 A JP2023528666 A JP 2023528666A JP 2023528666 A JP2023528666 A JP 2023528666A JP WO2022101470 A5 JPWO2022101470 A5 JP WO2022101470A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- final
- buffer
- rna
- anions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 206
- 150000002632 lipids Chemical class 0.000 claims description 88
- 238000000034 method Methods 0.000 claims description 72
- 239000000243 solution Substances 0.000 claims description 65
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 63
- 150000001450 anions Chemical class 0.000 claims description 53
- -1 citrate anions Chemical class 0.000 claims description 48
- 238000009472 formulation Methods 0.000 claims description 46
- 239000008346 aqueous phase Substances 0.000 claims description 43
- 239000007853 buffer solution Substances 0.000 claims description 40
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 36
- 239000012062 aqueous buffer Substances 0.000 claims description 30
- 239000012928 buffer substance Substances 0.000 claims description 30
- 239000002577 cryoprotective agent Substances 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 229920000642 polymer Polymers 0.000 claims description 17
- 230000007935 neutral effect Effects 0.000 claims description 15
- 150000003431 steroids Chemical class 0.000 claims description 15
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 claims description 14
- 229930006000 Sucrose Natural products 0.000 claims description 12
- 230000002163 immunogen Effects 0.000 claims description 12
- 239000005720 sucrose Substances 0.000 claims description 12
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 11
- 239000007983 Tris buffer Substances 0.000 claims description 11
- 239000000872 buffer Substances 0.000 claims description 11
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 11
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 229910052920 inorganic sulfate Inorganic materials 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 108700026244 Open Reading Frames Proteins 0.000 claims description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 8
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 238000010257 thawing Methods 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims description 6
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 6
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 claims description 6
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims description 6
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 6
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 claims description 6
- YKIOPDIXYAUOFN-UHFFFAOYSA-N 2,3-di(icosanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC YKIOPDIXYAUOFN-UHFFFAOYSA-N 0.000 claims description 6
- NEZDNQCXEZDCBI-UHFFFAOYSA-N 2-azaniumylethyl 2,3-di(tetradecanoyloxy)propyl phosphate Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-UHFFFAOYSA-N 0.000 claims description 6
- ZLGYVWRJIZPQMM-HHHXNRCGSA-N 2-azaniumylethyl [(2r)-2,3-di(dodecanoyloxy)propyl] phosphate Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCC ZLGYVWRJIZPQMM-HHHXNRCGSA-N 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 6
- 125000004450 alkenylene group Chemical group 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 6
- 235000014633 carbohydrates Nutrition 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 108010082974 polysarcosine Proteins 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000000600 sorbitol Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 150000005846 sugar alcohols Chemical class 0.000 claims description 6
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 claims description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
- 230000008014 freezing Effects 0.000 claims description 5
- 238000007710 freezing Methods 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 150000003904 phospholipids Chemical class 0.000 claims description 5
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 4
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 4
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000007865 diluting Methods 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 229910052816 inorganic phosphate Inorganic materials 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims description 4
- 229940045145 uridine Drugs 0.000 claims description 4
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 3
- LJARBVLDSOWRJT-UHFFFAOYSA-O 2-[2,3-di(pentadecanoyloxy)propoxy-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical compound CCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCC LJARBVLDSOWRJT-UHFFFAOYSA-O 0.000 claims description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 3
- 125000004406 C3-C8 cycloalkylene group Chemical group 0.000 claims description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 3
- 229930185560 Pseudouridine Natural products 0.000 claims description 3
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 claims description 3
- 229930182558 Sterol Natural products 0.000 claims description 3
- NJFCSWSRXWCWHV-USYZEHPZSA-N [(2R)-2,3-bis(octadec-1-enoxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCC=COC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC=CCCCCCCCCCCCCCCCC NJFCSWSRXWCWHV-USYZEHPZSA-N 0.000 claims description 3
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 229940106189 ceramide Drugs 0.000 claims description 3
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- 238000009295 crossflow filtration Methods 0.000 claims description 3
- 125000005724 cycloalkenylene group Chemical group 0.000 claims description 3
- VLBPIWYTPAXCFJ-XMMPIXPASA-N lysophosphatidylcholine O-16:0/0:0 Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C VLBPIWYTPAXCFJ-XMMPIXPASA-N 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 3
- 230000004962 physiological condition Effects 0.000 claims description 3
- 239000000651 prodrug Substances 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims description 3
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 3
- 150000003432 sterols Chemical class 0.000 claims description 3
- 235000003702 sterols Nutrition 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 101150077194 CAP1 gene Proteins 0.000 claims description 2
- 101150014715 CAP2 gene Proteins 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 claims description 2
- 238000011026 diafiltration Methods 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- IJFVSSZAOYLHEE-SSEXGKCCSA-N 1,2-dilauroyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC IJFVSSZAOYLHEE-SSEXGKCCSA-N 0.000 claims 1
- 101100245221 Mus musculus Prss8 gene Proteins 0.000 claims 1
- 101100260872 Mus musculus Tmprss4 gene Proteins 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 5
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 4
- 239000007993 MOPS buffer Substances 0.000 description 4
- 125000003835 nucleoside group Chemical group 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 101100438378 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) fac-1 gene Proteins 0.000 description 1
- 101100326803 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) fac-2 gene Proteins 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063114478P | 2020-11-16 | 2020-11-16 | |
| US63/114,478 | 2020-11-16 | ||
| US202063115588P | 2020-11-18 | 2020-11-18 | |
| US202063115128P | 2020-11-18 | 2020-11-18 | |
| EP2020082602 | 2020-11-18 | ||
| US63/115,588 | 2020-11-18 | ||
| US63/115,128 | 2020-11-18 | ||
| EPPCT/EP2020/082602 | 2020-11-18 | ||
| US202163135723P | 2021-01-10 | 2021-01-10 | |
| US63/135,723 | 2021-01-10 | ||
| US202163149372P | 2021-02-15 | 2021-02-15 | |
| US63/149,372 | 2021-02-15 | ||
| EPPCT/EP2021/059460 | 2021-04-12 | ||
| PCT/EP2021/059460 WO2022218503A1 (en) | 2021-04-12 | 2021-04-12 | Lnp compositions comprising rna and methods for preparing, storing and using the same |
| PCT/EP2021/081675 WO2022101470A1 (en) | 2020-11-16 | 2021-11-15 | Lnp compositions comprising rna and methods for preparing, storing and using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023549266A JP2023549266A (ja) | 2023-11-22 |
| JPWO2022101470A5 true JPWO2022101470A5 (https=) | 2024-11-22 |
| JP2023549266A5 JP2023549266A5 (https=) | 2024-11-22 |
Family
ID=78621901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023528666A Pending JP2023549266A (ja) | 2020-11-16 | 2021-11-15 | Ｒｎａを含むｌｎｐ組成物ならびにそれを調製、貯蔵および使用する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230414747A1 (https=) |
| EP (1) | EP4243788A1 (https=) |
| JP (1) | JP2023549266A (https=) |
| KR (1) | KR20230121752A (https=) |
| AU (1) | AU2021379090A1 (https=) |
| CA (1) | CA3198742A1 (https=) |
| IL (1) | IL302771A (https=) |
| MX (1) | MX2023005696A (https=) |
| TW (1) | TW202237148A (https=) |
| WO (1) | WO2022101470A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| CZ310443B6 (cs) | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| US12449081B2 (en) | 2021-09-24 | 2025-10-21 | Cosmo Koki Co., Ltd. | Boring machine |
| CN118488834A (zh) * | 2021-11-23 | 2024-08-13 | 赛欧生物医药股份有限公司 | 细菌源性脂质组合物和其用途 |
| US20250302747A1 (en) * | 2022-06-08 | 2025-10-02 | Academia Sinica | Lipids, nanoparticles comprising the same and uses thereof |
| CN114989182B (zh) * | 2022-06-23 | 2023-06-23 | 尧唐(上海)生物科技有限公司 | 脂质化合物、包含其的组合物及应用 |
| EP4604927A1 (en) * | 2022-10-17 | 2025-08-27 | Agilent Technologies, Inc. | Methods of analyzing lipid nanoparticles in physiological fluids |
| EP4637787A2 (en) * | 2022-12-20 | 2025-10-29 | Seqirus Inc. | Lipid nanoparticle composition |
| WO2024131874A1 (en) * | 2022-12-21 | 2024-06-27 | Abogen Biosciences (Shanghai) Co., Ltd. | Polynucleotides encoding cd19/cd3 bispecific antibodies |
| WO2024193827A1 (en) * | 2023-03-23 | 2024-09-26 | BioNTech SE | Stabilized nucleic acid compositions and methods for preparing, storing and using the same |
| WO2024203660A1 (ja) * | 2023-03-29 | 2024-10-03 | 国立大学法人東北大学 | 核酸内封脂質ナノ粒子の製造方法 |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025068553A1 (en) | 2023-09-28 | 2025-04-03 | Universität Basel | Catalytic moieties for treating cancer |
| WO2025080672A1 (en) * | 2023-10-09 | 2025-04-17 | The Trustees Of The University Of Pennsylvania | Immune cell targeted delivery vehicles and methods of use thereof |
| GB202404607D0 (en) * | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| US20180303925A1 (en) | 2015-04-27 | 2018-10-25 | The Trustees Of The University Of Pennsylvania | Nucleoside-Modified RNA For Inducing an Adaptive Immune Response |
| IL307179A (en) * | 2015-10-28 | 2023-11-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| BR112018069417A2 (pt) | 2016-04-22 | 2019-01-22 | Biontech Rna Pharmaceuticals Gmbh | método para fornecer rna fita simples e ssrna |
| WO2017218704A1 (en) * | 2016-06-14 | 2017-12-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| BR112019008481A2 (pt) | 2016-10-26 | 2020-03-03 | Curevac Ag | Vacinas de mrna de nanopartículas lipídicas |
| WO2020072605A1 (en) * | 2018-10-02 | 2020-04-09 | Intellia Therapeutics, Inc. | Ionizable amine lipids |
| JP2023511633A (ja) * | 2020-01-28 | 2023-03-20 | モデルナティエックス インコーポレイテッド | コロナウイルスｒｎａワクチン |
| EP3865122A1 (en) * | 2020-02-11 | 2021-08-18 | Pantherna Therapeutics GmbH | Lipid composition and use thereof for delivery of a therapeutically active agent to endothelium |
| US20240033344A1 (en) * | 2020-11-16 | 2024-02-01 | BioNTech SE | Pharmaceutical compositions comprising particles and mrna and methods for preparing and storing the same |
| AU2021376893A1 (en) * | 2020-11-16 | 2023-06-15 | BioNTech SE | Enhanced formulation stabilization and improved lyophilization processes |
-
2021
- 2021-11-15 AU AU2021379090A patent/AU2021379090A1/en active Pending
- 2021-11-15 EP EP21807117.3A patent/EP4243788A1/en active Pending
- 2021-11-15 KR KR1020237020261A patent/KR20230121752A/ko active Pending
- 2021-11-15 MX MX2023005696A patent/MX2023005696A/es unknown
- 2021-11-15 WO PCT/EP2021/081675 patent/WO2022101470A1/en not_active Ceased
- 2021-11-15 JP JP2023528666A patent/JP2023549266A/ja active Pending
- 2021-11-15 IL IL302771A patent/IL302771A/en unknown
- 2021-11-15 US US18/036,677 patent/US20230414747A1/en active Pending
- 2021-11-15 TW TW110142348A patent/TW202237148A/zh unknown
- 2021-11-15 CA CA3198742A patent/CA3198742A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022101470A5 (https=) | ||
| JPWO2022101486A5 (https=) | ||
| WO2022232585A9 (en) | Lyophilization methods for preparing lipid formulated therapeutics | |
| CA1322171C (en) | Liposome composition and its production | |
| US6235724B1 (en) | Injections containing lipid a analogues and process for the preparation thereof | |
| TWI896950B (zh) | 佐劑之製造方法 | |
| HU186296B (en) | Process for producing parenteral pharmaceutical compositions | |
| EP1274443B1 (en) | Micelles | |
| RU2012109405A (ru) | Композиции антагонистов нейрокинина-1 для внутривенного введения | |
| KR20250031230A (ko) | 핵산 전달을 위한 지질 나노입자 및 이의 사용 방법 | |
| WO2024046448A1 (en) | Lyophilized formulations and liquid formulations of lipid nanoparticles | |
| WO2013003306A1 (en) | Pharmaceutical compositions for parenteral administration | |
| Vora et al. | Bortezomib–first therapeutic proteasome inhibitor for cancer therapy: a review of patent literature | |
| US8541360B2 (en) | Parenteral formulations comprising sugar-based esters and ethers | |
| WO1989002265A1 (fr) | Emulsion grasse contenant un medicament, du type prepare immediatement avant l'utilisation, et procede de preparation d'une telle emulsion grasse contenant un medicament | |
| TW200520787A (en) | Liposome and drug deliver system | |
| RU2008121716A (ru) | Препараты | |
| US8992969B2 (en) | Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery | |
| KR101971451B1 (ko) | ２―하이드록시올레산이 포함된 지질 비히클의 용도 | |
| KR102772764B1 (ko) | 트레할로즈 유도체 및 신규 구조 유지 화합물을 포함하는 핵산 의약품 전달용 지질나노입자의 약학 조성물 | |
| JPWO2022218891A5 (https=) | ||
| JPWO2023009422A5 (https=) | ||
| JPWO2021163339A5 (https=) | ||
| JP2017122119A (ja) | 少なくとも１つのコレステロール誘導体を含むリポソーム | |
| JPH07121871B2 (ja) | インフルエンザワクチン凍結乾燥製剤 |